Cantor Fitzgerald Maintains Overweight on Lexeo Therapeutics, Raises Price Target to $37
Benzinga Newsdesk 3 days ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.
Cantor Fitzgerald analyst Kristen Kluska maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Overweight and raises the price target from $23 to $37.
